TranscriptsFeb. 26, 2025 11:22 PM ETVir Biotechnology, Inc. (VIR) StockVIRSA Transcripts152.36K FollowersVir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ETCompany ParticipantsRichard Lepke - Senior Director, Investor RelationsMarianne De Backer - Chief Executive OfficerMark Eisner - Executive Vice President & Chief Medical OfficerJason O’Byrne - Executive Vice President & Chief Financial OfficerMika Derynck - Executive Vice President of Therapeutic Head OncologyConference Call ParticipantsHang Hu - BarclaysPaul Choi - Goldman SachsPhil Nadeau - TD CowenAlec Stranahan - Bank of AmericaJoseph Stringer - NeedhamPatrick Trucchio - H.C. Wainwright & Co.OperatorHello. Welcome to Vir Biotechnology’s Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session. [Operator Instructions]I will now turn the call over to Rich Lepke, Senior Director, Investor Relations. You may begin, Mr. Lepke.Richard LepkeThank you and good afternoon. With me today are Dr. Marianne De Backer, our Chief Executive Officer; Dr. Mark Eisner, our Chief Medical Officer; Jason O'Byrne, our Chief Financial Officer; and Dr. Mika Derynck, our Executive Vice President of Oncology, will be available during the Q&A session.Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K. Please note that any cross-trial comparisons discussed today are notRead more current VIR analysis and newsView all earnings call transcriptsComments